Elligo Health Research® enables clinical trials through EHR data, proprietary technology, and access to diverse patients from various healthcare networks, self-described as integrating healthcare and research.

Elligo Health Research®

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

John Smith

Nicholas Babaian

GSK plc

Massive Bioinformatics provides bioinformatics and biotechnology solutions aimed at enhancing the quality of life through innovative products and services, self-described as a team of dedicated scientists and software engineers.

Massive Bioinformatics

Signant Health provides clinical trial technologies and services, generating clinical data.

Metric
Company Name	Elligo Health Research®	GSK plc	Massive Bioinformatics	Signant Health
Symbol		GSK
MSH ID	COM:ELLIGOHEALTHRESEARCH	COM:GSK	COM:MASSIVEBIOINFORMATICS	COM:VIRTRIAL
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Clinical Research	Drug Manufacturers - General	Biotechnology	Pharmaceuticals & Biotechnology
Country	US	GB	TR	US
Stage
Employee Count		70.21K
Website	elligohealthresearch.com	gsk.com	massivebioinformatics.com	virtrial.com
LinkedIn
Founders

Metric
Market Cap	786.32M
Enterprise Value
Monthly Web Traffic	1.33M	833
Web Traffic Growth	0.02	0.18
Valuation
Raised Capital

Metric
Revenue		38.64B
Revenue (LTM)
Revenue (NTM)
Gross Profit		27.08B
EBITDA		11.83B
Operating Income		8.91B
Net Income		6.28B
EPS		1.55
Diluted EPS		1.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.73
Operating Profit Margin		0.26
EBITDA Margin		0.31
Net Profit Margin		0.16
Return on Equity		0.39
Return on Assets		0.08
Return on Capital Employed		0.20

COM:ELLIGOHEALTHRESEARCH

Elligo Health Research®

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		11.10
P/B Ratio		5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.37
EV Multiple		5.83

Metric
Days Sales Outstanding
Days Payables Outstanding		678.29
Days Inventory Outstanding		247.86
Operating Cycle		338.14
Cash Conversion Cycle		-264.26
Asset Turnover		0.54

Metric
Operating Cash Flow		8.09B
Free Cash Flow		5.10B
Cash Flow to Debt		0.42
Operating Cash Flow/Sales		0.24
Free Cash Flow Yield		0.05

Metric
Cash & Equivalents		3.74B
Accounts Receivable		-826.97M
Inventory		7.01B
Goodwill		8.68B
Debt to Capitalization		0.56
Debt to Assets		0.34
Current Ratio		0.95
Quick Ratio		0.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.20
SG&A to Revenue		0.31